Abstract

The purpose of the Advocacy Core is to add another dimension to the scientific process and continue to improve the effectiveness of the translational aspects of the SPORE program. This Core supports the SPORE in many ways, from exploring innovative solutions from a survivor's perspective regarding issues in the Projects, to providing Advocate Liaisons for every Project, Core and key developmental grant projects. It's members contribute as independent individuals or from several different advocate organizations in the Bay Area. The Advocacy Core will continue its ground-breaking efforts by exploring various methods to increase awareness and, potentially, accrual to clinical trials.
Specific Aims :
AIM #1 : Identify barriers to clinical trial accrual and provide practical solutions that the Clinical Core and Advocacy Core and effectively implement in SPORE clinical trials.
AIM #2 : Measure results of the implemented solutions applied to SPORE clinical trials through an accural rate analysis and through survey results from targeted audiences.
AIM #3 : Contribute to the translational goals of the SPORE through active participation in all Projects and Cores. Methods: The Advocacy Core will analyze existing literature and conduct focus groups to identify barriers to clinical trials. Solutions may be initiated through educational presentations, Internet accessibility, newsletter articles, and clinical trial accrual analysis to complete its goals. The Clinical Trial Information Project (CTlP) is currently being developed by the Advocacy Core, and will be used in the design of the educational presentations. It is a community-based venture, and is forming a network of community research interests and advocacy groups that will be utilized to implement its aims. Collaboration with all existing infrastructures within the SPORE, including the Epidemiology and Biostatistical Core, the Clinical Core, each Project, and resources such as the Mt. Zion Cancer Resource Center and the CPMC Breast Clinic will also be used.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058207-07
Application #
6102854
Study Section
Project Start
1998-08-01
Project End
1999-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
7
Fiscal Year
1998
Total Cost
Indirect Cost

  Institution

Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143

  Publications

Rice, Megan S; Tamimi, Rulla M; Bertrand, Kimberly A et al. (2018) Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics. Breast Cancer Res Treat 170:129-141
Zhou, Yu; Zou, Hao; Yau, Christina et al. (2018) Discovery of internalizing antibodies to basal breast cancer cells. Protein Eng Des Sel 31:17-28
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Campbell, Michael J; Baehner, Frederick; O'Meara, Tess et al. (2017) Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat 161:17-28
Bolan, Patrick J; Kim, Eunhee; Herman, Benjamin A et al. (2017) MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging 46:290-302
Olow, Aleksandra; Chen, Zhongzhong; Niedner, R Hannes et al. (2016) An Atlas of the Human Kinome Reveals the Mutational Landscape Underlying Dysregulated Phosphorylation Cascades in Cancer. Cancer Res 76:1733-45
Takai, Ken; Le, Annie; Weaver, Valerie M et al. (2016) Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget 7:82889-82901
Hu, Zhi; Mao, Jian-Hua; Curtis, Christina et al. (2016) Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer. Breast Cancer Res 18:70
Malkov, Serghei; Shepherd, John A; Scott, Christopher G et al. (2016) Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status. Breast Cancer Res 18:122
Gu, Shenda; Hu, Zhi; Ngamcherdtrakul, Worapol et al. (2016) Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget 7:14727-41

Showing the most recent 10 out of 339 publications